Trial Profile

A phase I/II study of nicotinamide riboside (NR) in patients with Cockayne Syndrome

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
24 Nov 2016 New trial record
11 Nov 2016 According to a Chroma Technology Corporation media release, the company anticipates to file an investigational new drug application for the initiation of this trial in the first quarter of 2017. The FDA has indicated it will consider a Fast Track designation for nicotinamide riboside at the time of the IND submission.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com